Moderna (MRNA) Revenue (2017 - 2026)
Moderna (MRNA) posted quarterly Revenue of $145.0 million for Q2 2026, up 2.11% year-over-year from $142.0 million in Q2 2025, and down 62.72% on a QoQ basis from $389.0 million in Q1 2026.
Moderna (MRNA) Revenue (2017 - 2026) Analysis & Trends
Moderna has reported Revenue for 10 years, with the latest figure at $145.0 million in Q2 2026.
- Revenue for Q2 2026 came in at $145.0 million, up 2.11% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.2 billion (down 27.62% YoY), and the FY2025 annual result was $1.9 billion, down 39.93% from the prior year.
- Revenue eased to $145.0 million in Q2 2026, from $389.0 million in the prior quarter.
- Over five years, Revenue peaked at $6.1 billion in Q1 2022 and troughed at $108.0 million in Q1 2025.
- A 5-year average of $1.8 billion and a median of $991.0 million in 2024 frame the typical range for Revenue.
- The widest annual swing landed in 2023, when Revenue tumbled 92.76%; it then soared 260.19% in 2026.
- A 5-year view of Revenue shows it stood at $5.1 billion in 2022, then slumped by 44.71% to $2.8 billion in 2023, then tumbled by 65.64% to $966.0 million in 2024, then slipped by 29.81% to $678.0 million in 2025, then plunged by 78.61% to $145.0 million in 2026.
- Per Business Quant data, the three most recent Revenue figures were $145.0 million in Q2 2026, $389.0 million in Q1 2026, and $678.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 145.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 145.00 Mn |
| Mar 31, 2026 | 389.00 Mn |
| Dec 31, 2025 | 678.00 Mn |
| Sep 30, 2025 | 1.02 Bn |
| Jun 30, 2025 | 142.00 Mn |
| Mar 31, 2025 | 108.00 Mn |
| Dec 31, 2024 | 966.00 Mn |
| Sep 30, 2024 | 1.86 Bn |
| Jun 30, 2024 | 241.00 Mn |
| Mar 31, 2024 | 167.00 Mn |
| Dec 31, 2023 | 2.81 Bn |
| Sep 30, 2023 | 1.83 Bn |
| Jun 30, 2023 | 344.00 Mn |
| Mar 31, 2023 | 1.86 Bn |
| Dec 31, 2022 | 5.08 Bn |
| Sep 30, 2022 | 3.36 Bn |
| Jun 30, 2022 | 4.75 Bn |
| Mar 31, 2022 | 6.07 Bn |
| Dec 31, 2021 | 7.21 Bn |
| Sep 30, 2021 | 4.97 Bn |